BioMarin Pharmaceutical | BMRN - Pre Tax Profit

Stock Price
58.13
Daily Change
0.98 1.71%
Monthly
-5.19%
Yearly
-9.07%
Q1 Forecast
56.35

BioMarin Pharmaceutical reported $-26.32M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 44.6M 4.38M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Alnylam Pharmaceuticals USD 238.97M 274.33M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Bayer EUR -1.16B 735M Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Gilead Sciences USD 2.43B 780M Jun/2025
Incyte USD 482.31M 75.7M Sep/2025
Insmed USD -368.7M 48.26M Sep/2025
Ionis Pharmaceuticals USD -129M 253M Sep/2025
Moderna USD -187M 631M Sep/2025
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
PTC Therapeutics USD -23.07M 47.98M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sanofi EUR -1.16B 6.23B Dec/2025
Sarepta Therapeutics USD -194.05M 347.69M Sep/2025
Ultragenyx Pharmaceutical USD -179.54M 65.54M Sep/2025
United Therapeutics USD 438M 29.6M Sep/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025